Top Markets
Coin of the day
BioNexus Gene Lab Corp. BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp.

BGLC
Rang in aandelen #35594
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala... BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Aandeelprijs
$1.50
Laatst gesynchroniseerd: 2026-09-21
Marktkapitalisatie
$3.63M
Verandering (1 dag)
-4.46%
Verandering (1 jaar)
-72.68%
Land
MY
Handel BioNexus Gene Lab Corp. (BGLC)

Categorie

Winst voor BioNexus Gene Lab Corp. (BGLC)
Winst in Jun 2026 TTM: $-2.58M
Volgens de meest recente financiële verslagen van BioNexus Gene Lab Corp. bedraagt de huidige winst van het bedrijf $-2.58M. In 2023 behaalde het bedrijf een winst van $-2.61M, een daling ten opzichte van de winst van 2022, die $-303.66K bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van BioNexus Gene Lab Corp. van 2016 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-2.58M 61.47%
2024 $-1.59M -38.84%
2023 $-2.61M 758.71%
2022 $-303.66K -129.12%
2021 $1.04M -17.40%
2020 $1.26M -557.92%
2019 $-275.71K -560.27%
2018 $59.90K -150.16%
2017 $-119.41K 14,201.08%
2016 $-835.00 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$2.69B -104,366.42%
US
$1.78B -69,051.75%
US
- -
US
$934.20M -36,377.72%
US
- -
US